Leukotriene B4 triggers release of the cathelicidin LL-37 from human neutrophils: novel lipid-peptide interactions in innate immune responses.
Wan. Min M; Sabirsh. Alan A; Wetterholm. Anders A; Agerberth. Birgitta B; Haeggström. Jesper Z JZ
Key Findings
- Leukotriene B4 at nanomolar levels triggers rapid release of LL‑37 from human neutrophils
- LL‑37 feeds back to increase leukotriene B4 production, especially when cells are primed
- The LL‑37 and leukotriene B4 loop enhances neutrophil phagocytosis of bacteria
Practical Outcomes
- For biohackers, the work suggests that stimulating the LTB4‑LL‑37 pathway could strengthen innate immunity, but the research is limited to lab cells and does not provide dosage or safe ways to apply it in humans.
Summary
The study shows that a lipid called leukotriene B4 can quickly make immune cells release the antimicrobial peptide LL‑37, and LL‑37 in turn helps cells make more leukotriene B4, boosting the cells' ability to eat bacteria.
Abstract
In humans, the antimicrobial peptide LL-37 and the potent chemotactic lipid leukotriene B4 (LTB4) are important mediators of innate immunity and host defense. Here we show that LTB4, at very low (1 nM) concentrations, strongly promotes release of LL-37 peptides from human neutrophils (PMNs) in a time- and dose-dependent manner, as determined by Western blot, enzyme-linked immunoassay (ELISA), and antibacterial activity. The LTB4-induced LL-37 release is mediated by the BLT1 receptor, and protein phosphatase-1 (PP-1) inhibits the release by suppressing the BLT1-mediated exocytosis of PMN granules. Conversely, LL-37 elicits translocation of 5-lipoxygenase (5-LO) from the cytosol to the perinuclear membrane in PMNs and promotes the synthesis and release of LTB4, particularly from cells primed with LPS or GM-CSF. Furthermore, LL-37 stimulates PMN phagocytosis of Escherichia coli particles, a functional response that is enhanced by LTB4, especially in GM-CSF pretreated cells. In these cells, LL-37 also enhances LTB4-induced phagocytosis. Hence, in human PMNs, positive feedback circuits exist between LL-37 and LTB4 that reciprocally stimulate the release of these mediators with the potential for synergistic bioactions and enhanced immune responses. Moreover, these novel lipid-peptide signaling pathways may offer new opportunities for pharmacological intervention and treatment of chronic inflammatory diseases.
Study Information
pubmed
2007
2007-04-19T00:00:00.000Z
10.1096/fj.06-7974com
82
46